<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Platelet collagen receptor <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> VI (GPVI) contributes significantly to platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to investigate GPVI in patients presenting with symptoms of <z:hpo ids='HP_0011009'>acute</z:hpo> cerebrovascular disease and to define GPVI as biomarker for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We consecutively evaluated 205 patients, who admitted the <z:hpo ids='HP_0001297'>stroke</z:hpo> unit with symptoms for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Surface expression of the platelet activation markers (GPVI, CD62P, GPIb) was determined by two-color whole blood flow cytometry </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) (n = 18; 8.8%) as well as with <z:hpo ids='HP_0001297'>stroke</z:hpo> (n = 133; 64.9%) showed a significantly enhanced GPVI expression (mean fluorescence intensity +/- SD) on admission compared to patients with non-ischemic (NI) events (n = 54; 26.3%) (<z:hpo ids='HP_0002326'>TIA</z:hpo>: 20.9 +/- 7.1 vs. NI: 16.2 +/- 3.9; P = 0.002; <z:hpo ids='HP_0001297'>stroke</z:hpo>: 20.4 +/- 5.7 vs. NI; P = 0.002) </plain></SENT>
<SENT sid="5" pm="."><plain>Neither CD62P nor GPIb surface expression showed a significant difference </plain></SENT>
<SENT sid="6" pm="."><plain>Logistic regression analysis revealed that on admission GPVI was associated with <z:hpo ids='HP_0001297'>stroke</z:hpo> independent of conventional laboratory markers such as C-reactive protein, blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, and <z:chebi fb="2" ids="16919">creatine</z:chebi> kinase </plain></SENT>
<SENT sid="7" pm="."><plain>Using a receiver operating characteristic curve on GPVI, we have determined the cut off value of 18.2 for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, patients with enhanced GPVI expression levels (&gt;or=18.2) had a 2.4-fold relative risk for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with elevated platelet GPVI expression level had a poorer clinical outcome in cumulative event-free survival for <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, and cerebro-/cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> at 3-month follow-up (log rank; P = 0.045) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: These findings indicate that platelet GPVI surface expression is significantly enhanced in patients with <z:hpo ids='HP_0002326'>TIA</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo> compared to patients with NI events </plain></SENT>
<SENT sid="11" pm="."><plain>Determination of platelet-specific GPVI may be useful as an early biomarker for <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>